Michele Francesco Chiappetta
Overview
Explore the profile of Michele Francesco Chiappetta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barbaro F, Papparella L, Chiappetta M, Schepis T, Maresca R, Del Vecchio L, et al.
Eur J Gastroenterol Hepatol
. 2025 Feb;
PMID: 39976048
Background And Aim: Endoscopic mucosal resection (EMR) of superficial nonampullary duodenal epithelial tumors (SNADETs) is challenging, and to date, only a few studies assessed the clinical outcomes of EMR in...
2.
Maselli R, De Sire R, Barbaro F, Cecinato P, Andrisani G, Rosa Rizzotto E, et al.
Endoscopy
. 2025 Jan;
PMID: 39848273
Background: Patients with inflammatory bowel disease (IBD) have an increased risk of colorectal cancer. High-risk colorectal colitis-associated neoplasia (HR-CAN) can be difficult to treat using traditional endoscopic resection methods. This...
3.
Barbaro F, Papparella L, Chiappetta M, Ciuffini C, Fukuchi T, Hamanaka J, et al.
Eur J Gastroenterol Hepatol
. 2023 Dec;
36(2):162-167.
PMID: 38131424
Background And Aims: Endoscopic treatment of recurrent/residual colonic lesions on scars is a challenging procedure. In this setting, endoscopic submucosal dissection (ESD) is considered the first choice, despite a significant...
4.
Pecere S, Chiappetta M, Del Vecchio L, Despott E, Dray X, Koulaouzidis A, et al.
Best Pract Res Clin Gastroenterol
. 2023 Aug;
64-65:101857.
PMID: 37652655
No abstract available.
5.
Schepis T, De Lucia S, Pellegrino A, Del Gaudio A, Maresca R, Coppola G, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444534
Pancreatic cancer remains a social and medical burden despite the tremendous advances that medicine has made in the last two decades. The incidence of pancreatic cancer is increasing, and it...
6.
Papa V, Schepis T, Coppola G, Chiappetta M, Del Vecchio L, Rozera T, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370753
Pancreatic cancer (PC) has an unfavorable prognosis with few effective therapeutic options. This has led researchers to investigate the possible links between microbiota and PC. A disrupted gut microbiome can...
7.
Barbaro F, Ciuffini C, Chiappetta M, Papparella L, Pecere S, Ricci R, et al.
Dig Liver Dis
. 2023 Jun;
55(10):1391-1396.
PMID: 37316365
Background And Aims: To date, western data on colorectal ESD are limited. This study aimed to assess the efficacy and safety of rectal ESD for superficial lesions ≥ 8 cm....
8.
Pecere S, Ciuffini C, Chiappetta M, Petruzziello L, Papparella L, Spada C, et al.
Expert Rev Anticancer Ther
. 2023 Apr;
23(6):583-591.
PMID: 37099725
Introduction: Colorectal cancer (CRC) is a major health issue, being responsible for nearly 10% of all cancer-related deaths. Since CRC is often an asymptomatic or paucisymptomatic disease until it reaches...
9.
Viola A, Demarzo M, Abbruzzese A, Muscianisi M, Chiappetta M, Costantino G, et al.
Patient Prefer Adherence
. 2023 Mar;
17:807-816.
PMID: 36992866
Purpose: New therapeutic approaches for ulcerative colitis (UC) are now available, but there is still no robust evidence for predictors of poor outcomes. We aimed to evaluate the factors associated...
10.
Chiappetta M, Viola A, Mastronardi M, Turchini L, Carparelli S, Orlando A, et al.
Expert Opin Biol Ther
. 2021 Sep;
21(11):1483-1489.
PMID: 34521307
Background: Efficacy and safety of ustekinumab for the treatment of ulcerative colitis (UC) has been demonstrated in clinical trials, but few real-world data are available so far. The aim of...